---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-042338"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:32:05.586921+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Unicycive Q1 net loss $21.2M ($0.61/sh); OLC pivotal topline due Q2 2024

## Summary
- Net loss $21.2M ($0.61/sh) vs $14.8M ($0.97) in Q1 2023; R&D expenses rose to $6.8M from $3.0M.
- Cash $48.9M at March 31, 2024; funded operations expected into 2026.
- Topline data from OLC pivotal trial in CKD on dialysis expected in Q2 2024.
- UNI-494 Phase 1 MAD portion ongoing; FDA orphan drug designation for prevention of DGF in kidney transplant.
- Completed $50M private placement with healthcare institutional investors.

## SEC filing metadata
- accession: 0001213900-24-042338
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/0001213900-24-042338-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/ea0205889-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-042338
- JSON: https://secwatch.observer/filing/0001213900-24-042338.json
- Plain text: https://secwatch.observer/filing/0001213900-24-042338.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported the three months ended March 31, 2024 results: net income Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s, EPS $0.61 per share of common stock.
  - Period: the three months ended March 31, 2024
  - Net income: Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per s
  - EPS: $0.61 per share of common stock
  - Result: reported results
  source text: Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”) , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced its financial results for the three months ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390024042338/0001213900-24-042338-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.